ROS1 and non-small cell lung carcinoma: The U.S. Food and Drug Administration (FDA) has since approved entrectinib for the treatment of adults with ROS1 fusion-positive, metastatic non-small cell lung cancer (NSCLC) and granted accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with NTRK fusion-positive solid tumors [7].